Arab Finance: The Tenth of Ramadan for Pharmaceuticals Industries and Diagnostic Reagents (Rameda) has acquired 11 medicines for the treatment of chronic diseases, such as diabetes and high cholesterol, from a leading pharmaceuticals player in Egypt, according to a press release on June 1st.
The acquisition will enable the company to enter five fast-growing therapeutic fields, with a total market value of EGP 2.2 billion.
Rameda is a leading Egyptian pharmaceutical company that develops and produces a wide range of branded generic pharmaceuticals, nutraceuticals, food supplements, and veterinary products.